API | aleglitazar

aleglitazar Report issue

Small molecule Experimental

AACT ChEMBL DrugBank PubChem

Active Ingredient History

NOW

Aleglitazar is a peroxisome proliferator-activated receptor agonist with affinity to PPARα and PPARγ, which was under development by Hoffmann–La Roche for the treatment of type II diabetes. It is no longer in phase III clinical trials. ^Wikipedia

Chemistry

SMILES: CO[C@@H](Cc1ccc(OCCc2nc(oc2C)c3ccccc3)c4ccsc14)C(=O)O
InChIKey: DAYKLWSKQJBGCS-NRFANRHFSA-N
Mol. Mass: 437.52
ALogP: 5.13 Partition coefficient
ChEMBL Molecule:
aleglitazar

More Chemistry

Pharmacology

Mechanisms of Action:
- Peroxisome proliferator-activated receptor alpha (Homo sapiens) ^UniProt
- Peroxisome proliferator-activated receptor gamma (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

aleglitazar | r-1439 | ro-0728804

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (2)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (2)

Diabetes Mellitus, Type 2 (Phase 3)

Healthy Volunteers (Phase 1)

Overview

Highest Phase: Phase 3
# of Trials: 22
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue